ASCO 2025: Key Clinical Trials in Resectable NSCLC
Key Points
-
Promising findings regarding neoadjuvant treatment in patients with resectable non-small cell lung cancer (NSCLC) were presented at the 2025 American Society of Clinical Society (ASCO) Annual Meeting.
-
The CheckMate 816 trial demonstrated a statistically and clinically significant overall survival benefit at 5 years with neoadjuvant nivolumab plus chemotherapy in NSCLC.
-
Neoadjuvant osimertinib with or without chemotherapy showed statistically significant improvement in major pathological response in the NeoADAURA study.
Pivotal clinical studies presented at the 2025 ASCO Annual Meeting showed promising findings that could benefit patients with early-stage resectable NSCLC.
Eric Singhi, MD, of The University of Texas MD Anderson Cancer Center, showcased the CheckMate 816 and NeoADAURA trials while speaking with Mitchell Alexander Parma, MD, also of MD Anderson.
He discussed potential clinical implications of the CheckMate 816 study, which showed a significant overall survival (OS) benefit in updated findings presented at ASCO. Neoadjuvant nivolumab plus chemotherapy demonstrated a 5-year OS rate of 65% compared with 55% with chemotherapy alone.
Dr. Singhi also shared his excitement about the NeoADAURA study, which evaluated neoadjuvant osimertinib in combination with chemotherapy versus chemotherapy alone in patients with resectable EGFR-mutated NSCLC . Participants were randomized 1:1:1 to either receive the combination, osimertinib alone, or chemotherapy alone. Data presented at ASCO showed that osimertinib significantly improved major pathological response (MPR)—the study’s primary end point—compared with chemotherapy. In the osimertinib plus chemotherapy and osimertinib monotherapy arms, the MPR rate was 26% and 25%, respectively, versus an MPR rate of 2% in the chemotherapy alone arm.